(Q34220004)

31 July 2017

1 reference

title

An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults (English)

1 reference

attention deficit hyperactivity disorder

31 July 2017

0 references

0 references

1 reference

Timothy E Wilens

1

1 reference

31 July 2017

Nicholas R Morrison

series ordinal

2

1 reference

31 July 2017

Jefferson Prince

series ordinal

3

1 reference

31 July 2017

publication date

1 October 2011

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

31 July 2017

published in

1 reference

31 July 2017

volume

11

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

1443-1465

1 reference

Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An Open Trial of Sustained Release Bupropion for Attention-Deficit/Hyperactivity Disorder in Adults with ADHD plus Substance Use Disorders.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

The intersection of attention-deficit/hyperactivity disorder and substance abuse

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Clinical assessment and diagnosis of adults with attention-deficit/hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Understanding attention-deficit/hyperactivity disorder from childhood to adulthood

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Long-term safety of stimulant medications used to treat children with ADHD.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Diagnosing attention-deficit/hyperactivity disorder in patients with substance use disorders.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Psychopharmacological interventions

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Comparing the efficacy of medications for ADHD using meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Stimulants and sudden death: what is a physician to do?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

ADHD drugs and cardiovascular risk

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Diagnostic controversies in adult attention deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A clinical perspective of attention-deficit/hyperactivity disorder into adulthood

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Cognitive effects of nicotine

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

The stimulants revisited.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

The neurobiology of attention-deficit/hyperactivity disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Six-year predictors of problems in a national sample: IV. Young adult signs of disturbance

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Open-label trial of venlafaxine in adults with attention deficit disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Amphetamine: effects on catecholamine systems and behavior

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Clinical correlates of methylphenidate blood levels.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Methylphenidate effects on symptoms of attention deficit disorder in adults.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open trial of pargyline in the treatment of attention deficit disorder, residual type

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Propranolol for adults with temper outbursts and residual attention deficit disorder.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Neuropharmacology of methylphenidate and a neural substrate for childhood hyperactivity.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Nomifensine maleate in adult attention deficit disorder

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

S-adenosyl-L-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Stimulant drug treatment of hyperactivity: biochemical correlates.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Combination of treatments for attention deficit hyperactivity disorder in adults.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Hyperactive boys almost grown up. V. Replication of psychiatric status.

28 July 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Nervous habits and stereotyped behaviors in preschool children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Emotional dysregulation in adult ADHD and response to atomoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Efficacy of meta-cognitive therapy for adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Open-label trial of atomoxetine hydrochloride in adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Identification of the human cytochromes P450 responsible for atomoxetine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Sensorimotor transformation deficits for smooth pursuit in first-episode affective psychoses and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229037

Axis I and II comorbidity in adults with ADHD

28 October 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

A Randomized, Single-Blind, Substitution Study of OROS Methylphenidate (Concerta) in ADHD Adults Receiving Immediate Release Methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.11.137

Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: A statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association

21 January 2018

1 reference

12 December 2020

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in

1 reference

12 December 2020

A double-blind trial of bupropion in children with attention deficit disorder

1 reference

12 December 2020

An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder

1 reference

12 December 2020

A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder

1 reference

12 December 2020

A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder

1 reference

12 December 2020

A one year trial of methylphenidate in the treatment of ADHD

1 reference

12 December 2020

Bupropion treatment of attention-deficit hyperactivity disorder in adults

1 reference

12 December 2020

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults

1 reference

12 December 2020

Attention deficit disorder ('minimal brain dysfunction') in adults. A replication study of diagnosis and drug treatment

1 reference

12 December 2020

Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children

1 reference

12 December 2020

Effects of levodopa on attention deficit disorder, residual type

1 reference

12 December 2020

A controlled study of autonomic nervous system function in adults with attention-deficit/hyperactivity disorder treated with stimulant medications: results of a pilot study

1 reference

12 December 2020

Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial

1 reference

12 December 2020

Treatment of attention deficit disorder with DL-phenylalanine

1 reference

12 December 2020

Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety

1 reference

12 December 2020

Identifiers

DOI

10.1586/ERN.11.137

1 reference

31 July 2017

1 reference

31 July 2017

1 reference